We are also further increasing our investment behind selected brands to ensure performance accelerates. Finally, I would highlight that our new product portfolio will expand this quarter with the addition of repotrectinib next month and, upon completion of the Mirati transaction, Krazati. Turning now to our R&D Engine on Slide 8. As I mentioned last month, we have exciting opportunities to strengthen our pipeline and deliver more important medicines to patients across therapeutic areas, including expanding our registrational pipeline from six to 12 assets over the next 18 months.